USA flag logo/image

An Official Website of the United States Government

Whole-brain fluorescence and brightfield imaging at single-cell level

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95697
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
AG035446
Solicitation Year:
N/A
Solicitation Topic Code:
NIA
Solicitation Number:
N/A
Small Business Information
DMETRIX, INC.
9030 South Rita Rd Ste 389 TUCSON, AZ -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Whole-brain fluorescence and brightfield imaging at single-cell level
Agency: HHS
Contract: 1R44AG035446-01
Award Amount: $977,235.00
 

Abstract:

DESCRIPTION (provided by applicant): The goal of this project is to develop an open and flexible imaging platform capable of rapid, 0.5- 5 m pixel resolution image capture of large-area histology sections (up to 125 mm by 175 mm), in brightfield and by ep i-fluorescence optical sectioning. The project involves state-of-the- art instrumentation development coupled with application programming interfaces (APIs) to provide users with a reliable, multi-purpose research instrument. The development of a high spee d large format imaging system will dramatically accelerate investigations such as amyloid protein studies for Alzheimer's disease or the expression of immediate-early genes (IEG) in understanding of the cellular basis of cognition. The number of digital-im aging system options decreases dramatically as the size of histology sections outgrows 1 W 3 glass slides. Further, because the current vendors are concentrating on digitizing anatomic pathology, their systems tend to be closed and inflexible to accommod ate the regulatory constraints on medical devices. The market opportunity that DMetrix has identified is a robust and reliable commercial imaging platform with the flexibility and customization options valued by research groups. The project is divided into two Phases, punctuated by a demonstration of quantitative criteria, related to instrument and software performance. The primary goal of Phase I is the demonstration of feasibility of the large-area, rapid imaging instrument for brightfield and epi-fluores cence. A second goal is an image-viewer application that allows practical interaction with terabyte image data sets as will be generated by the instrument. The Specific Aims of Phase II are selected to lead to a product launch at the conclusion of the proj ect. The Phase II Aims include the development of a V6, six-imaging-module slide scanner, image- management software, and an advanced image-viewer application. Further, the work in Phase II leverages the core expertise of DMetrix, namely the development of fast, parallel image-capture instruments. A significant part of the Phase II effort will be directed at making the proposed instrument manufacturable at a minimum cost of goods sold (COGS) and optimized for serviceability. DMetrix has teamed on this pro ject with an interdisciplinary group of academic experts from the University of Arizona. The University team includes Dr. Carol Barnes from the McKnight Brain Institute, Dr. Ted Trouard, Department of Radiology and Biomedical Engineering, and Dr. Gene Alex ander, Director of the Brain Imaging, Behavior and Aging Lab in the Department of Psychology. These University of Arizona scientists represent a diverse sampling of the broad impact of the proposed imaging platform on neuroscience research. PUBLIC H EALTH RELEVANCE: Understanding the circuits in the brain responsible for cognition, emotion and action is a critical first step to developing treatments for important neurological disorders, such as Alzheimer's disease, Parkinson's disease, temporal lobe e pilepsy, depression, and schizophrenia. Collectively, these disorders affect over 20 million Americans. Our long-range goal is to develop a system that has wide application across the field of neuroscience that will enable experiments impeded in the past b y technological limitations, to span mouse models of disease to rat and nonhuman primate models of normal aging. This knowledge may bring us closer to optimizing neural function in health, and developing new therapies for patients disabled by neurological disease.

Principal Investigator:

Lloyd J. Lacomb

Business Contact:

Lloyd J. Lacomb
jzhou@dmetrix.com
Small Business Information at Submission:

DMETRIX, INC.
PO Box 41540 TUCSON, AZ -

EIN/Tax ID: 186103658
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No